Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling.
Glycosylation can exert a profound impact on the structures and biological functions of antibodies. Glycosylation remodeling using the endoglycosidase-catalyzed deglycosylation and transglycosylation approach is emerging as a promising platform to produce homogeneous glycoforms of antibodies, but the broad application of this method will require the availability of highly efficient glycosynthase mutants. We describe in this paper a systematic site-directed mutagenesis of an endoglycosidase from Streptococcus pyogenes of serotype M49 (Endo-S2) and the evaluation of the resulting mutants for their hydrolysis and transglycosylation activities. We found that mutations at the Asp-184 residue gave mutants that demonstrated significantly different properties, some possessed potent transglycosylation activity with diminished hydrolysis activity but others did not, which would be otherwise difficult to predict without the comparative study. In contrast to the previously reported Endo-S mutants that are limited to action on complex type N-glycans, the Endo-S2 glycosynthases described here, including D184M and D184Q, were found to have remarkably relaxed substrate specificity and were capable of transferring three major types (complex, high-mannose, and hybrid type) of N-glycans for antibody glycosylation remodeling. In addition, the Endo-S2 glycosynthase mutants were found to be much more active in general than the Endo-S mutants for transglycosylation. The usefulness of these Endo-S2 glycosynthase mutants was exemplified by an efficient glycosylation remodeling of two therapeutic monoclonal antibodies, rituximab and trastuzumab (Herceptin).
From the Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742.
Tiezheng
T
Li
From the Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742.
Xin
X
Tong
From the Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742.
Qiang
Q
Yang
From the Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742.
John P
JP
Giddens
From the Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742 wang518@umd.edu.
Lai-Xi
LX
Wang
D001426:Bacterial Proteins / Q000737:chemistry* / Q000235:genetics; D006026:Glycoside Hydrolases / Q000737:chemistry* / Q000235:genetics; D006031:Glycosylation; D006868:Hydrolysis; D009154:Mutation; D000069283:Rituximab / Q000737:chemistry*; D013297:Streptococcus pyogenes / Q000201:enzymology* / Q000235:genetics; D013379:Substrate Specificity / Q000235:genetics; D000068878:Trastuzumab / Q000737:chemistry*
D001426:Bacterial Proteins; D000069283:Rituximab; D006026:Glycoside Hydrolases; C431325:NDOS protein, Streptococcus pyogenes; D000068878:Trastuzumab
Herceptin; antibody engineering; chemoenzymatic synthesis; glycoengineering; glycoprotein; glycosidase; glycosylation; glycosynthase; monoclonal antibody; transglycosylation